Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer (Zabton-PC) study

被引：1
|
作者：
Ueno, Satoru
Mizokami, Atsushi
Fukagai, Takashi
Fujimoto, Naohiro
Ohoka, Hitoshi
Kondo, Yukihiro
Arai, Gaku
Ide, Hisamitsu
Namiki, Mikio
机构：
[1] Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan
[2] Showa Univ, Sch Med, Tokyo 142, Japan
[3] Univ Occupat & Environm Hlth, Kitakyushu, Japan
[4] Kobe Med Ctr, Natl Hosp Org, Kobe, Hyogo, Japan
[5] Nippon Med Sch, Dept Urol, Tokyo 113, Japan
[6] Dokkyo Med Univ, Koshigaya Hosp, Saitama, Japan
[7] Teikyo Univ Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
207
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: Prevention by zoledronic acid.
    Padalecki, SS
    Carreon, MR
    Grubbs, B
    Cui, Y
    Guise, TA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S310 - S310
  • [22] Maximal androgen blockade (MAS) for the treatment of prostate cancer
    Kirby, RS
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1996, 50 (05): : 287 - 287
  • [23] Estramustine, zoledronic acid and weekly docetaxel in metastatic androgen independent prostate cancer (MAIP).
    Nasr, FL
    Chahine, GY
    Moukaddem, WT
    Farhat, FS
    Tueini, EA
    Kattan, JG
    Dagher, JE
    Younes, FC
    Ghosn, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 440S - 440S
  • [24] Baseline bone metabolism markers as predictors for progression-free survival of patients with treatment-naive bone-metastatic prostate cancer treated with zoledronic acid plus combined androgen blockade
    Nozawa, M.
    Inagaki, T.
    Nagao, K.
    Nishioka, T.
    Komura, T.
    Esa, A.
    Kitagawa, M.
    Imanishi, M.
    Uekado, Y.
    Ogawa, T.
    Kajikawa, H.
    Uejima, S.
    Matsuyama, H.
    Hara, I
    Uemura, H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E125 - U513
  • [25] Recommendations for use of zoledronic acid (Z) for prevention and treatment of osteoporosis in men on androgen deprivation therapy (ADT) for prostate cancer (PC)
    Pandya, M. B.
    Broderick, W.
    Campbell, S. C.
    Garewal, H.
    Friedman, N.
    Moritz, T.
    Reda, D.
    Bhoopalam, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Insulin sensitivity during combined androgen blockade for prostate cancer
    Smith, MR
    Lee, H
    Nathan, DM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (04): : 1305 - 1308
  • [27] Combined androgen blockade: The gold standard for metastatic prostate cancer
    McLeod, DG
    Crawford, ED
    DeAntoni, EP
    EUROPEAN UROLOGY, 1997, 32 : 70 - 77
  • [28] Zoledronic acid for hormone-naive prostate cancer with bone metastasis.
    Nozawa, Masahiro
    Hara, Isao
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    Uemura, Hirotsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer
    Weinfurt, KP
    Anstrom, KJ
    Castel, LD
    Schulman, KA
    Saad, F
    ANNALS OF ONCOLOGY, 2006, 17 (06) : 986 - 989
  • [30] Presence of Giant Osteoclasts in Zoledronic Acid Treated Prostate Cancer Bone Metastasis
    Roudier, Martine P.
    Morrissey, Colm
    Dowell, Alexander
    Corey, Eva
    Higano, Celestia
    True, Lawrence
    Vessella, Robert
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
12345